title: Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.
abstract: In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well tolerated and safe. Serum and brain creatine concentrations increased in the creatine-treated group and returned to baseline after washout. Serum 8-hydroxy-2'-deoxyguanosine (8OH2'dG) levels, an indicator of oxidative injury to DNA, were markedly elevated in HD and reduced by creatine treatment.
authors.affiliation: Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. hersch@helix.mgh.harvard.edu
authors.forename: S M
authors.initials: SM
authors.lastname: Hersch
authors.forename: S
authors.initials: S
authors.lastname: Gevorkian
authors.forename: K
authors.initials: K
authors.lastname: Marder
authors.forename: C
authors.initials: C
authors.lastname: Moskowitz
authors.forename: A
authors.initials: A
authors.lastname: Feigin
authors.forename: M
authors.initials: M
authors.lastname: Cox
authors.forename: P
authors.initials: P
authors.lastname: Como
authors.forename: C
authors.initials: C
authors.lastname: Zimmerman
authors.forename: M
authors.initials: M
authors.lastname: Lin
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: A M
authors.initials: AM
authors.lastname: Ulug
authors.forename: M F
authors.initials: MF
authors.lastname: Beal
authors.forename: W
authors.initials: W
authors.lastname: Matson
authors.forename: M
authors.initials: M
authors.lastname: Bogdanov
authors.forename: E
authors.initials: E
authors.lastname: Ebbel
authors.forename: A
authors.initials: A
authors.lastname: Zaleta
authors.forename: Y
authors.initials: Y
authors.lastname: Kaneko
authors.forename: B
authors.initials: B
authors.lastname: Jenkins
authors.forename: N
authors.initials: N
authors.lastname: Hevelone
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: H
authors.initials: H
authors.lastname: Yu
authors.forename: D
authors.initials: D
authors.lastname: Schoenfeld
authors.forename: R
authors.initials: R
authors.lastname: Ferrante
authors.forename: H D
authors.initials: HD
authors.lastname: Rosas
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000328:Adult; D001682:Biological Availability; D015415:Biomarkers / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D003401:Creatine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
chemical_list: D015415:Biomarkers; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine; D003401:Creatine